In a bombshell revelation that could reshape the wearable tech landscape, industry analyst Juan Kołos (via Twitter) claims Apple is preparing a groundbreaking Apple Watch with non-invasive glucose monitoring alongside the rugged Apple Watch Ultra 3. According to Kołos, both devices are slated for a September 2025 launch, aligning with Apple’s traditional fall event.
The Glucose Monitoring Breakthrough
For years, Apple has quietly pursued "Project Everest" – an ambitious endeavor to integrate non-invasive blood glucose tracking into the Apple Watch. Kołos’ report suggests this feature will finally debut in a new sensor-equipped model, possibly branded as the "Apple Watch Series X" or a special health edition.
https://unsplash.com/de/fotos/nahaufnahme-einer-person-die-eine-apple-watch-tragt-BNJjDz3tdqA
Image: The next-gen Apple Watch may revolutionize health tracking. (Source: Unsplash)
The technology reportedly uses optical sensors and AI algorithms to measure glucose levels through the skin, eliminating finger-prick blood tests. If successful, this could be a lifeline for diabetics and a massive leap for preventive healthcare.
Apple Watch Ultra 3: What’s New?
The third-generation Ultra model is expected to target adventurers with key upgrades:
- Brighter MicroLED Display (3,000+ nits) for harsh environments
- Extended 72-hour battery life in low-power mode
- Enhanced Dive Computer for deeper underwater tracking
- New titanium finishes (including matte black)
Release Timeline & Pricing
Per Kołos’ tweet (view full analysis here), Apple’s 2025 lineup will include:
- September 2025: Flagship launch event for glucose-capable Apple Watch and Ultra 3.
- October 2025: Wider retail availability.
Pricing is rumored to start at $799 for the glucose model (requiring FDA clearance) and $899 for the Ultra 3.
Current Deals on Older Models
While we await Apple’s next-gen watches, retailers are discounting existing models:
- Apple Watch Series 10 at historic low: $329 on Amazon (originally $499).
- Clearance sales on Ultra 2: GSMArena reports up to 40% off at major outlets.
Analyst Insights
Kołos cautions that regulatory hurdles could delay the glucose monitor’s rollout outside the U.S. However, Apple’s healthcare partnerships (like its work with Medtronic) suggest confidence in the tech. As he tweeted:
"This isn’t just an upgrade—it’s Apple’s play to own the future of personal health."
The Bottom Line
If Kołos’ intel holds, Apple’s 2025 wearables could blur the line between consumer tech and medical devices. With shares of glucose-monitoring stocks dipping on the news, it’s clear Wall Street sees the disruption coming. Pre-orders are expected to open September 12.
Stay updated via our tech newsletter [subscribe link].
Post a Comment